FGFR2 and gastric cancer: LC-MB12, an Infigratinib-based PROTAC, selectively degrades FGFR2 and effectively inhibits the proliferation of TEL–FGFR2 fusion-positive Ba/F3 cells and FGFR2-overexpressing gastric cancer cells (SNU16).232